Industry: Global GCPs, Final Rule Should Precede FDA Foreign Study Guidance
This article was originally published in The Gray Sheet
Medical device makers are concerned about a lack of globally harmonized standards for good clinical practices, which they say could cause problems for a guidance FDA has drafted on studies conducted outside the U.S.
You may also be interested in...
A run-down of key provisions impacting the medical device and diagnostics industry in the 21st Century Cures legislation, which passed the House by a 344-77 vote July 10.
FDA has been accepting data from patients outside of the U.S. to support device approvals for years, but the sponsor should check with the agency in advance to ensure the foreign data meets the needs of the U.S. regulatory system, according to a new draft guidance. The guidance details the factors that could stand in the way of FDA accepting foreign data and provides examples of what could be done about it.
AdvaMed says FDA’s proposed rule on requiring foreign studies to follow good clinical practice guidelines should not be finalized until an international medical device and IVD clinical guideline has been established and adopted.